B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.